Anti-human IgM antibody as well as preparation method and application thereof
By providing specific antibodies or functional fragments thereof, the problem of interference between rheumatoid factors and heterophilic antibodies in the prior art is solved, and efficient blocking effect is achieved, and the accuracy and reliability of immune detection are improved.
Patent Information
- Application Number
- CN202310614535.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-27
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2043-05-27
AI Technical Summary
In existing antibody detection, rheumatoid factors and heterophilic antibody interfering substances are difficult to effectively block, resulting in inaccurate detection results. The existing blockers have limited effects and rely on high concentration addition, and cannot effectively block multiple heterophilicities. Antibody.
An antibody or functional fragment thereof is provided that specifically binds to human IgM protein and contains a specific amino acid sequence for use as a blocker in immune detection, which can efficiently neutralize interfering substances and reduce endogenous interference.
This antibody or its functional fragment can effectively block a variety of interfering substances, provide a higher blocking effect at low concentrations, significantly improve the accuracy and reliability of the detection results, and is suitable for a variety of analytical conditions.
Smart Images

Figure CN119039449A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of antibody technology, and in particular to an anti-human IgM antibody and a preparation method and use thereof. Background Art
[0002] Immunoassay methods based on antigen-antibody reactions are widely used and are divided into different detection methods according to antibody markers, such as enzyme-linked immunosorbent assay, radioimmunoassay, chemiluminescence, etc. In clinical applications, the accuracy of immunoassay results is often affected to varying degrees by interferences in patient serum, resulting in erroneous test results. Interferences in serum can be divided into endogenous interference and exogenous interference. Exogenous interference includes hemolysis, specimen contamination, incomplete blood coagulation, sample stability and storage conditions, etc.; endogenous interference includes rheumatoid factor (RF), heterophilic antibody (HA), autoantibodies, complement, jaundice, high fat, etc. Among them, rheumatoid factor (RF) and heterophilic antibody (HA) are important interference factors. Studies have confirmed that about 3-15% of healthy people have endogenous interference factors in their bodies, more than 10% (30-40%) of patients have heterophilic antibodies (HA), and 10-40% of the population have HAMA interference. Among endogenous interferences, rheumatoid factor and heterophilic antibody (HA) are the most common. Therefore, studying effective means to reduce or eliminate the interference of rheumatoid factors and heterophilic antibodies (HA) is an important topic to ensure the reliability of medical immunoassay results. The simplest and most effective way to eliminate the interference of rheumatoid factors and heterophilic antibodies (HA) in immunodiagnosis is to add blocking agents to the detection system to directly block the binding of interfering substances with antibodies or antigens in the detection system.
[0003] Blockers are biological agents that are added to the immunoassay system and can react with endogenous antibodies, thereby effectively preventing non-analyte-mediated antibody bridging. Blockers can be divided into passive blockers and active blockers. Passive blockers use non-specific substances (such as mouse IgG, mouse serum, non-specific monoclonal antibodies, aggregated IgG, etc.) to block the binding of human heterologous antibodies, such as MAK33 and MAB33 in commercial reagents. This type of reagent has limited use and can only block an active reagent of human anti-specific animal antibodies (such as human anti-mouse antibodies). The blocking effect depends on the affinity of human heterologous antibodies. Usually, the affinity of human heterologous antibodies is usually around 10. -5 -10 -6 Therefore, during the use of passive blockers, high concentrations are often added to reduce interference. In addition, heterophilic interference involves many components, and different passive blockers are required to block different types of heterophilic antibodies.
[0004] Active blockers are specific to human immunoglobulins and can specifically, actively and efficiently neutralize the components of interfering antibodies, thereby blocking the generation of unintended binding, such as IIR and HBR in commercial reagents. This preparation can eliminate various heterophilic interferences, has specific binding force to heterophilic antibodies that cause interference, and only requires low concentrations to effectively block, minimizing the impact. IIR is a mixed mouse McAb produced by HA and HAAA as immunogens, which has a high affinity for HAAA. HBR is a mouse anti-human IgM McAb. In the active blocking process, the effect of eliminating interference depends on the affinity of the active agent for heterophilic antibodies. Due to the high affinity of active blockers, the blocking ability in some analyses is stronger than that of passive blockers. Therefore, providing a blocker with good performance is very valuable in the market. Summary of the invention
[0005] The present application provides an antibody or a functional fragment thereof, which has good binding reaction activity to human IgM and has good blocking and immune interference elimination effects for immunoassay, and provides an important source of blocking agent raw materials.
[0006] To achieve the above-mentioned object, according to one aspect of the present invention, an antibody or a functional fragment thereof is provided, which binds to human IgM protein and comprises three complementary determining regions having a heavy chain variable region of any one of the amino acid sequences of SEQ ID NO: 17, 18, 38, 56, 74, 92, 93, 94, 95, 120, 138, 177, 195, 214, 232, 250, 268, 286, 304, 322 or 340 and three complementary determining regions having a light chain variable region of any one of the amino acid sequences of SEQ ID NO: 19, 39, 57, 75, 96, 121, 139, 140, 141, 142, 143, 144, 145, 146, 178, 196, 215, 233, 251, 269, 287, 305, 323 or 341.
[0007] To achieve the above-mentioned object, according to a second aspect of the present invention, there is provided an antibody or a functional fragment thereof, comprising a heavy chain variable region and / or a light chain variable region, wherein the amino acid sequence of the heavy chain variable region is as shown in any one of SEQ ID NO: 17, 18, 38, 56, 74, 92, 93, 94, 95, 120, 138, 177, 195, 214, 232, 250, 268, 286, 304, 322 or 340; the amino acid sequence of the light chain variable region is as shown in any one of SEQ ID NO: 19, 39, 57, 75, 96, 121, 139, 140, 141, 142, 143, 144, 145, 146, 178, 196, 215, 233, 251, 269, 287, 305, 323 or 341.
[0008] To achieve the above-mentioned object, according to the third aspect of the present invention, there is provided an antibody or a functional fragment thereof, comprising a heavy chain and / or a light chain, wherein the amino acid sequence of the heavy chain is as shown in any one of SEQ ID NO: 20, 21, 40, 58, 76, 97, 98, 99, 100, 122, 147, 179, 197, 216, 234, 252, 270, 288, 306, 324, 342; the amino acid sequence of the light chain is as shown in any one of SEQ ID NO: 22, 41, 59, 77, 101, 123, 148, 149, 150, 151, 152, 153, 154, 155, 180, 198, 217, 235, 253, 271, 289, 307, 325, 343.
[0009] In order to achieve the above object, according to the fourth aspect of the present invention, a nucleic acid is provided, wherein the nucleic acid encodes any one of the antibodies or functional fragments thereof described above.
[0010] In order to achieve the above object, according to the fifth aspect of the present invention, a cell is provided, wherein the cell comprises the above nucleic acid.
[0011] In order to achieve the above object, according to the sixth aspect of the present invention, a method for preparing any of the above antibodies or functional fragments thereof is provided, the method comprising culturing the above cells.
[0012] In order to achieve the above object, according to the seventh aspect of the present invention, there is provided the use of the above antibody or its functional fragment in immunoassay or in the preparation of immunoblocking agent.
[0013] In order to achieve the above object, according to the eighth aspect of the present invention, a blocking agent is provided, wherein the blocking agent comprises the above antibody or a functional fragment thereof.
[0014] In order to achieve the above object, according to the ninth aspect of the present invention, a detection reagent or kit is provided, wherein the reagent or kit comprises the above antibody or its functional fragment or the above blocking agent.
[0015] In order to achieve the above object, according to the tenth aspect of the present invention, a method for reducing / eliminating endogenous interference is provided, wherein the above antibody or its functional fragment or the above blocker is added to the immunoassay system.
[0016] In order to achieve the above object, according to the eleventh aspect of the present invention, there is provided an immunoassay method, comprising: adding the above antibody or its functional fragment or the above blocking agent into an immunoassay system.
[0017] In order to achieve the above-mentioned object, according to the twelfth aspect of the present invention, a method for detecting IgM is provided, the method comprising: contacting the antibody or its functional fragment described in any one of the above items with a sample from the subject under conditions sufficient for a binding reaction to occur to perform a binding reaction; and detecting the immune complex produced by the binding reaction. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0019] Figure 1 The figure shows the result of reducing SDS-PAGE of Anti-hIgM Rmb1. DETAILED DESCRIPTION
[0020] In the first aspect, an embodiment of the present invention provides an antibody or a functional fragment thereof, which binds to human IgM protein and comprises three complementary determining regions of a heavy chain variable region having an amino acid sequence of any one of SEQ ID NO: 17, 18, 38, 56, 74, 92, 93, 94, 95, 120, 138, 177, 195, 214, 232, 250, 268, 286, 304, 322 or 340 and three complementary determining regions of a light chain variable region having an amino acid sequence of any one of SEQ ID NO: 19, 39, 57, 75, 96, 121, 139, 140, 141, 142, 143, 144, 145, 146, 178, 196, 215, 233, 251, 269, 287, 305, 323 or 341.
[0021] It should be noted that HCDR1, HCDR2 and HCDR3 are amino acid sequences consistent with HCDR1, HCDR2 and HCDR3 of the same heavy chain variable region defined in the antibody or its functional fragment described in the first aspect, and LCDR1, LCDR2 and LCDR3 are amino acid sequences consistent with LCDR1, LCDR2 and LCDR3 of the same light chain variable region defined in the antibody or its functional fragment described in the first aspect.
[0022] For example, the HCDR1, HCDR2, and HCDR3 are amino acid sequences consistent with HCDR1, HCDR2, and HCDR3 of the heavy chain variable region shown in SEQ ID NO: 17; the LCDR1, LCDR2, and LCDR3 are amino acid sequences consistent with LCDR1, LCDR2, and LCDR3 of the light chain variable region shown in SEQ ID NO: 19.
[0023] Under the Kabat definition, the amino acid sequences of HCDR1, HCDR2 and HCDR3 of the heavy chain variable region SEQ ID NO:17 are shown as SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, respectively, and the amino acid sequences of HCDR1, HCDR2 and HCDR3 of the antibody or its functional fragment are also shown as SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, respectively.
[0024] Under the Kabat definition, the amino acid sequences of LCDR1, LCDR2 and LCDR3 of the light chain variable region SEQ ID NO:19 are shown in SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6, respectively, and the amino acid sequences of LCDR1, LCDR2 and LCDR3 of the antibody or its functional fragment are also shown in SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6, respectively.
[0025] In the present invention, the term "antibody" is used in the broadest sense and may include full-length monoclonal antibodies, bispecific or multispecific antibodies, and chimeric antibodies, so long as they exhibit the desired biological activity.
[0026] In the present invention, the term "complementarity determining region", "CDR" or "CDRs" refers to the highly variable region of the heavy and light chains of immunoglobulins, and refers to the region containing one or more or even all of the major amino acid residues that play a role in the binding of an antibody or antigen-binding fragment to its recognized antigen or epitope. In a specific embodiment of the present invention, CDRs refers to the highly variable region of the heavy and light chains of the antibody.
[0027] In the present invention, the heavy chain complementarity determining region is represented by HCDR, which includes HCDR1, HCDR2 and HCDR3; the light chain complementarity determining region is represented by LCDR, which includes LCDR1, LCDR2 and LCDR3.
[0028] The definition methods of CDR are well known in the art, and the CDR definition methods include: Kabat definition, Chothia definition, IMGT definition, Contact definition and AbM definition. As described herein, "Kabat definition" refers to the definition system described in Kabat et al., US Pept. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983). "Chothia definition" refers to Chothia et al., J Mol Biol 196: 901-917 (1987). There are other CDR definition methods that may not strictly follow one of the above schemes, but will still overlap with at least a portion of the CDR region defined by Kabat, although they may be shortened or extended based on predictions or experimental results of specific residues or residue groups. Exemplary defined CDRs are listed in Table 1 below, and the annotations in different documents are slightly different. Given the variable region amino acid sequence of an antibody, a person skilled in the art can routinely determine which residues contain a specific CDR. It should be noted that CDRs defined by other methods not limited to those in Table 1 also fall within the scope of protection of the present disclosure.
[0029] Table 1: CDR Definition 1
[0030] CDR Kabat <![CDATA[AbM 2 ]]> IMGT Chothia HCDR1 <![CDATA[H31~H35 3 ]]> <![CDATA[H26~H35 3 ]]> <![CDATA[H26~H33..5 5 ]]> <![CDATA[H26~H32..34 4 ]]> HCDR2 H50 - H65 H50 - H58 H51 - H57 H52 - H56 HCDR3 H95 - H102 H95 - H102 H93 - H102 H95 - H102 LCDR1 L24 - L34 L24 - L34 L27 - L32 L24 - L34 LCDR2 L50 - L56 L50 - L56 L50 - L51 L50 - L56 LCDR3 L89 - L97 L89 - L97 L89 - L97 L89 - L97
[0031] 1 The numbering of all CDR definitions in Table 1 is based on the Kabat numbering system (see below), with the amino acid numbering on the heavy chain represented by "H+number" and the amino acid numbering on the light chain represented by "L+number". One of ordinary skill in the art can unambiguously map the Kabat numbering system to any variable region sequence without relying on any experimental data other than the sequence itself. As used herein, "Kabat numbering" refers to the numbering system described by Kabat et al., U.S. Patent. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983).
[0032] 2"AbM" as used in Table 1 with a lowercase "b" refers to CDRs defined by Oxford Molecular's "AbM" antibody modeling software.
[0033] 3 If both H35A and H35B are absent, CDR-H1 ends at position 35; if only H35A is present, CDR-H1 ends at position 35A; if both H35A and H35B are present, CDR-H1 ends at position 35B.
[0034] 4 If both H35A and H35B are absent, CDR-H1 ends at position 32; if only H35A is present, CDR-H1 ends at position 33; if both H35A and H35B are present, CDR-H1 ends at position 34.
[0035] 5 If both H35A and H35B are absent, CDR-H1 ends at position 33; if only H35A is present, CDR-H1 ends at position 34; if both H35A and H35B are present, CDR-H1 ends at position 35.
[0036] According to an embodiment of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 or LCDR3 is defined by any one system or a combination of multiple systems of Kabat, Chothia, IMGT, AbM or Contact.
[0037] In some optional embodiments of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by the Kabat system.
[0038] In some optional embodiments of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by the Chothia system.
[0039] In some optional embodiments of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by the IMGT system.
[0040] In some optional embodiments of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by the AbM system.
[0041] In some optional embodiments of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by a Contact system.
[0042] In some optional embodiments of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by a combination of Kabat, Chothia, IMGT, AbM or Contact systems.
[0043] According to an embodiment of the present invention, the Kabat numbering positions corresponding to the amino acid sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 or LCDR3 defined by the Kabat, Chothia, AbM or IMGT systems are as follows:
[0044] CDR Kabat AbM IMGT Chothia HCDR1 H31 - H35 H26 - H35 H26 - H33 H26 - H32 HCDR2 H50 - H65 H50 - H58 H51 - H57 H52 - H56 HCDR3 H95 - H102 H95 - H102 H93 - H102 H95 - H102 LCDR1 L24 - L34 L24 - L34 L27 - L32 L24 - L34 LCDR2 L50 - L56 L50 - L56 L50 - L51 L50 - L56 LCDR3 L89 - L97 L89 - L97 L89 - L97 L89 - L97
[0045] According to an embodiment of the present invention, the HCDRs and LCDRs are defined by the Kabat system.
[0046] In an optional embodiment, an embodiment of the present invention provides an antibody or a functional fragment thereof, wherein the antibody or the functional fragment thereof comprises a CDR sequence of any of the following numbered combinations:
[0047]
[0048]
[0049] In the present invention, the "framework region" or "FR" region includes the heavy chain framework region and the light chain framework region, and refers to the region other than the CDR in the heavy chain variable region and the light chain variable region of the antibody; wherein the heavy chain framework region can be further subdivided into adjacent regions separated by CDR, including HFR1, HFR2, HFR3 and HFR4 framework regions; the light chain framework region can be further subdivided into adjacent regions separated by CDR, including LFR1, LFR2, LFR3 and LFR4 framework regions.
[0050] In the present invention, the heavy chain variable region is obtained by arranging and connecting the following numbered CDRs and FRs in the following combinations: HFR1-HCDR1-HFR2-HCDR2-HFR3-HCDR3-HFR4; the light chain variable region is obtained by arranging and connecting the following numbered CDRs and FRs in the following combinations: LFR1-LCDR1-LFR2-LCDR2-LFR3-LCDR3-LFR4.
[0051] In an optional embodiment, the antibody or a functional fragment thereof comprises a FR sequence of any of the following numbered combinations or has at least 80% identity with any of the numbered combinations of FRs:
[0052]
[0053]
[0054] It should be noted that, in other embodiments, the amino acid sequences of each framework region of the antibodies or functional fragments thereof provided by the present invention may be at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the above-mentioned corresponding framework regions.
[0055] In a second aspect, an embodiment of the present invention provides an antibody or a functional fragment thereof, comprising a heavy chain variable region and / or a light chain variable region, wherein the amino acid sequence of the heavy chain variable region is as shown in any one of SEQ ID NO: 17, 18, 38, 56, 74, 92, 93, 94, 95, 120, 138, 177, 195, 214, 232, 250, 268, 286, 304, 322 or 340; the amino acid sequence of the light chain variable region is as shown in any one of SEQ ID NO: 19, 39, 57, 75, 96, 121, 139, 140, 141, 142, 143, 144, 145, 146, 178, 196, 215, 233, 251, 269, 287, 305, 323 or 341.
[0056] In an optional embodiment, the antibody or functional fragment thereof described in the first aspect or the second aspect above comprises any combination of the following heavy chain variable regions and light chain variable regions:
[0057]
[0058]
[0059] In an alternative embodiment, the antibody or a functional fragment thereof further comprises a constant region.
[0060] In an alternative embodiment, the constant region includes a heavy chain constant region and / or a light chain constant region.
[0061] In an alternative embodiment, the heavy chain constant region is selected from the heavy chain constant region of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD, and the light chain constant region is selected from the κ type or λ type light chain constant region.
[0062] In an alternative embodiment, the constant region is derived from a species of cow, horse, dairy cow, pig, sheep, rat, mouse, dog, cat, rabbit, donkey, deer, mink, chicken, duck, goose, turkey, fighting cock or human.
[0063] In an alternative embodiment, the species origin of the constant region is mouse.
[0064] In an optional embodiment, the heavy chain constant region sequence (CH) is as shown in SEQ ID NO:15, 119, 213, and the light chain constant region (CL) sequence is as shown in SEQ ID NO:16.
[0065] It should be noted that, in other embodiments, the constant region sequence may have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with the above-mentioned constant region (SEQ ID NO: 15 or 16).
[0066] In an optional embodiment, the functional fragment is selected from any one of F(ab')2, Fab', Fab, Fv and scFv of the antibody.
[0067] The functional fragments of the above antibodies usually have the same binding specificity as the antibodies from which they are derived. It is easy for a person skilled in the art to understand based on the contents described in the present invention that the functional fragments of the above antibodies can be obtained by methods such as enzymatic digestion (including pepsin or papain) and / or by chemical reduction to split disulfide bonds. Based on the structure of the complete antibody disclosed in the present invention, a person skilled in the art can easily obtain the above functional fragments.
[0068] The functional fragments of the above antibodies can also be synthesized by recombinant genetic techniques known to those skilled in the art or by, for example, an automatic peptide synthesizer, such as those sold by Applied BioSystems.
[0069] In a third aspect, the present invention provides an antibody or a functional fragment thereof, comprising a heavy chain and / or a light chain, wherein the amino acid sequence of the heavy chain is as shown in any one of SEQ ID NO: 20, 21, 40, 58, 76, 97, 98, 99, 100, 122, 147, 179, 197, 216, 234, 252, 270, 288, 306, 324, and 342; the amino acid sequence of the light chain is as shown in any one of SEQ ID NO: 22, 41, 59, 77, 101, 123, 148, 149, 150, 151, 152, 153, 154, 155, 180, 198, 217, 235, 253, 271, 289, 307, 325, and 343.
[0070] In an optional embodiment, the antibody described in the first aspect, the second aspect, and the third aspect comprises any combination of the following heavy chains and light chains:
[0071] Combination Heavy chain Light chain 1 SEQ ID NO:20 SEQ ID NO:22 2 SEQ ID NO:21 SEQ ID NO:22 3 SEQ ID NO:40 SEQ ID NO:41 4 SEQ ID NO:58 SEQ ID NO:59 5 SEQ ID NO:76 SEQ ID NO:77 6 SEQ ID NO:97 SEQ ID NO:101 7 SEQ ID NO:98 SEQ ID NO:101 8 SEQ ID NO:99 SEQ ID NO:101 9 SEQ ID NO:100 SEQ ID NO:101 10 SEQ ID NO:122 SEQ ID NO:123 11 SEQ ID NO:147 SEQ ID NO:148 12 SEQ ID NO:147 SEQ ID NO:149 13 SEQ ID NO:147 SEQ ID NO:150 14 SEQ ID NO:147 SEQ ID NO:151 15 SEQ ID NO:147 SEQ ID NO:152 16 SEQ ID NO:147 SEQ ID NO:153 17 SEQ ID NO:147 SEQ ID NO:154 18 SEQ ID NO:147 SEQ ID NO:155 19 SEQ ID NO:179 SEQ ID NO:180 20 SEQ ID NO:197 SEQ ID NO:198 21 SEQ ID NO:216 SEQ ID NO:217 22 SEQ ID NO:234 SEQ ID NO:235 23 SEQ ID NO:252 SEQ ID NO:253 24 SEQ ID NO:270 SEQ ID NO:271 25 SEQ ID NO:288 SEQ ID NO:289 26 SEQ ID NO:306 SEQ ID NO:307 27 SEQ ID NO:324 SEQ ID NO:325 28 SEQ ID NO:342 SEQ ID NO:343
[0072] The present invention also provides a nucleic acid encoding any of the above antibodies or functional fragments thereof.
[0073] The present invention also provides a cell, wherein the cell comprises the above-mentioned nucleic acid.
[0074] The present invention also provides a method for preparing any of the above antibodies or functional fragments thereof, the method comprising culturing the above cells.
[0075] The present invention provides the use of the above-mentioned antibody or its functional fragment in immunoassay or in the preparation of an immunoblocker. The blocker can be used in combination on a chemiluminescence platform, a fluorescent immunochromatography platform, and a colloidal gold platform, and has a good blocking effect.
[0076] The present invention provides a blocking agent, which comprises the above-mentioned antibody or a functional fragment thereof.
[0077] Optionally, the concentration of the antibody in the blocking agent is 5-100 μg / ml.
[0078] The present invention provides a detection reagent or a test kit, wherein the reagent or the test kit comprises the above-mentioned antibody or its functional fragment or the above-mentioned blocking agent.
[0079] The present invention provides a method for reducing / eliminating endogenous interference, wherein the above-mentioned antibody or its functional fragment or the above-mentioned blocking agent is added to an immune detection system.
[0080] The present invention provides an immunoassay method, comprising: adding the above-mentioned antibody or its functional fragment or the above-mentioned blocking agent into an immunoassay system.
[0081] The present invention provides a method for detecting IgM, the method comprising: contacting any of the above-mentioned antibodies or functional fragments thereof with a sample from the subject under conditions sufficient for a binding reaction to proceed; and detecting the immune complex produced by the binding reaction.
[0082] Based on the amino acid sequence of the antibody or its functional fragment disclosed in the present invention, those skilled in the art can easily think of using genetic engineering technology or other technologies (chemical synthesis, recombinant expression) to prepare the antibody or its functional fragment, for example, separating and purifying the antibody or its functional fragment from the culture product of a recombinant cell that can recombinantly express the antibody or its functional fragment as described in any of the above items, which is easy to achieve for those skilled in the art. Based on this, no matter what technology is used to prepare the antibody or its functional fragment of the present invention, it belongs to the protection scope of the present invention.
[0083] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0084] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used for the practice or testing of the preparations or unit doses herein, some methods and materials are now described. Unless otherwise stated, the techniques adopted or considered herein are standard methods. Materials, methods and examples are illustrative and non-restrictive only.
[0085] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, molecular biology (including recombinant techniques), microbiology, biochemistry, and immunology, which are within the capabilities of a skilled artisan. This technique is fully explained in the literature, such as Molecular Cloning: A Laboratory Manual, 2nd Edition (Sambrook et al., 1989); Oligonucleotide Synthesis (MJ Gait, ed., 1984); Animal Cell Culture (RI Freshney, ed., 1987); Methods in Enzymology (Academic Press, Inc.); Handbook of Experimental Immunology (DM Weir and CC Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells (JM Miller and MP Calos, eds., 1987); Current Protocols in Molecular Biology (FM Ausubel et al., eds., 1987); PCR: The Polymerase Chain Reaction (PCR: The Polymerase Chain Reaction) (Academic Press, Inc.); Reaction" (Mullis et al., eds., 1994); and Current Protocols in Immunology (JE Coligan et al., eds., 1991), each of which is expressly incorporated herein by reference.
[0086] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0087] Example 1 Preparation of Anti-IgM Monoclonal Antibody
[0088] In this example, restriction endonucleases and Prime Star DNA polymerase were purchased from Takara. MagExtractor-RNA extraction kit was purchased from TOYOBO. BD SMART TMThe RACE cDNA Amplification Kit was purchased from Takara. The pMD-18T vector was purchased from Takara. The plasmid extraction kit was purchased from Tiangen. Primer synthesis and gene sequencing were completed by Invitrogen. The hybridoma cell lines secreting Anti-IgM monoclonal antibodies were the existing hybridoma monoclonal cell lines AbM1 to AbM28, which were revived for future use.
[0089] (1) Antibody gene preparation
[0090] mRNA was extracted from hybridoma monoclonal cell lines AbM1 to AbM28, and DNA products were obtained by RT-PCR. The products were inserted into pMD-18T vector after A addition reaction with rTaq DNA polymerase and transformed into DH5α competent cells. After colonies grew, Heavy Chain and Light Chain gene clones were obtained respectively, and 4 clones each were sent to a gene sequencing company for sequencing.
[0091] (2) Sequence analysis of the variable region gene of Anti-IgM antibody
[0092] The gene sequences obtained by the above sequencing were placed in the KABAT antibody database for analysis, and VNTI11.5 software was used for analysis to determine that the genes amplified by the heavy chain and light chain primer pairs were correct.
[0093] (3) Construction of recombinant antibody expression plasmid
[0094] pcDNA TM 3.4 vector is a recombinant antibody eukaryotic expression vector constructed, which has introduced multiple cloning restriction sites such as HindIII, BamHI, and EcoRI, and is named pcDNA3.4A expression vector, hereinafter referred to as 3.4A expression vector; according to the sequencing results of the antibody variable region genes in the above pMD-18T, the VL and VH gene-specific primers of the antibody were designed, with HindIII, EcoRI restriction sites and protective bases at both ends, respectively, and the 0.70-0.75kb Light Chain gene fragment and the 1.40-1.45kb Heavy Chain gene fragment were amplified by the PCR amplification method.
[0095] The Heavy Chain and Light Chain gene fragments were double-digested with HindIII / EcoRI, and the 3.4A vector was double-digested with HindIII / EcoRI. After the fragments and vectors were purified and recovered, the Heavy Chain gene and the Light Chain gene were respectively connected to the 3.4A expression vector to obtain the recombinant expression plasmids of the hybridoma monoclonal cell lines AbM1~AbM28 Heavy Chain and Light Chain, respectively.
[0096] 2. Recombinant Antibody Production
[0097] Resuscitate HEK293 cells in advance and subculture them to 200 ml system to make the cell density reach 3-5×10 6 cells / ml, the cell density reaches the selected antibody concentration and cells, and the cell viability is >95%; the cells are washed by centrifugation and re-dissolved with culture medium, and the cell density is adjusted to 2.9×10 6 cells / ml, wash the cells, re-dissolve with culture medium, and use it as cell diluent. Prepare the above 28 plasmid DNAs and transfection reagent diluents with culture medium respectively. Add the transfection reagent diluent to the 28 plasmid DNA diluents, mix well and let stand at room temperature for 15 minutes; slowly add the mixture to the cell diluent within 1 minute, take samples and count after mixing, record and observe the viability of the cells after transfection, and place them in a 35℃ constant temperature incubator for culture, with a speed of 120rmp and a CO2 content of 8%. Centrifuge and collect samples after 13 days. The centrifuged supernatant was affinity purified using a proteinA affinity chromatography column. Take 6ug layer of purified antibodies for reducing SDS-PAGE, and the electrophoresis is shown in the figure. After reducing SDS-PAGE, two bands are shown, one Mr is 50KD (heavy chain) and the other Mr is 28KD (light chain).
[0098] The obtained antibodies were named Anti-IgM Rmb1 to Anti-IgM Rmb28. The sequences of the heavy chain (H) and light chain (L) of the above antibodies are shown in the following table:
[0099] Table 2 Antibody sequences
[0100] Antibody Name Heavy Chain Light Chain Anti-IgM Rmb1 SEQ ID NO:20 SEQ ID NO:22 Anti-IgM Rmb2 SEQ ID NO:21 SEQ ID NO:22 Anti-IgM Rmb3 SEQ ID NO:40 SEQ ID NO:41 Anti-IgM Rmb4 SEQ ID NO:58 SEQ ID NO:59 Anti-IgM Rmb5 SEQ ID NO:76 SEQ ID NO:77 Anti-IgM Rmb6 SEQ ID NO:97 SEQ ID NO:101 Anti-IgM Rmb7 SEQ ID NO:98 SEQ ID NO:101 Anti-IgM Rmb8 SEQ ID NO:99 SEQ ID NO:101 Anti-IgM Rmb9 SEQ ID NO:100 SEQ ID NO:101 Anti-IgM Rmb10 SEQ ID NO:122 SEQ ID NO:123 Anti-IgM Rmb11 SEQ ID NO:147 SEQ ID NO:148 Anti-IgM Rmb12 SEQ ID NO:147 SEQ ID NO:149 Anti-IgM Rmb13 SEQ ID NO:147 SEQ ID NO:150 Anti-IgM Rmb14 SEQ ID NO:147 SEQ ID NO:151 Anti-IgM Rmb15 SEQ ID NO:147 SEQ ID NO:152 Anti-IgM Rmb16 SEQ ID NO:147 SEQ ID NO:153 Anti-IgM Rmb17 SEQ ID NO:147 SEQ ID NO:154 Anti-IgM Rmb18 SEQ ID NO:147 SEQ ID NO:155 Anti-IgM Rmb19 SEQ ID NO:179 SEQ ID NO:180 Anti-IgM Rmb20 SEQ ID NO:197 SEQ ID NO:198 Anti-IgM Rmb21 SEQ ID NO:216 SEQ ID NO:217 Anti-IgM Rmb22 SEQ ID NO:234 SEQ ID NO:235 Anti-IgM Rmb23 SEQ ID NO:252 SEQ ID NO:253 Anti-IgM Rmb24 SEQ ID NO:270 SEQ ID NO:271 Anti-IgM Rmb25 SEQ ID NO:288 SEQ ID NO:289 Anti-IgM Rmb26 SEQ ID NO:306 SEQ ID NO:307 Anti-IgM Rmb27 SEQ ID NO:324 SEQ ID NO:325 Anti-IgM Rmb28 SEQ ID NO:342 SEQ ID NO:343
[0101] Example 2 Performance testing of antibodies
[0102] 1. Activity and subclass identification
[0103] Coating solution (main component NaHCO3) dilution human IgM (purchased from Feipeng Bio) to 500 or 100ug / ml, 100uL per well, 4℃ overnight; the next day, wash twice with washing solution (main component Na2HPO4+Nacl), pat dry; add blocking solution (20% BSA+80% PBS), 120uL per well, 37℃, 1h, pat dry; add diluted purified antibody, 100uL / well, 37℃, 30min; wash 5 times with washing solution, pat dry; add goat anti-mouse IgG1-HRP, goat anti-mouse IgG2a-HRP or goat anti-mouse IgG2b-HRP, 100uL per well, 37℃, 30min; wash 5 times with washing solution, pat dry; add color developing solution A (50uL / well), add color developing solution B (50uL / well), 10min; add stop solution, 50uL / well; read OD value at 450nm (reference 630nm) on the microplate reader.
[0104] Table 3 Activity and subclass identification data
[0105]
[0106] 2. Performance evaluation
[0107] 2.1 Verify the blocking effect of the above anti-hIgM series antibodies (IgG1 subclass) on the chemiluminescence platform HIV p24 antibody pairing
[0108] HIV p24 antibody (IgG1 subclass, purchased from Feipeng Bio) was paired, coupled with magnetic beads and acridinium ester, respectively, and the following reaction procedure was used on the chemiluminescence instrument ishine2910: 50ul sample, 50ul magnetic bead working solution, 50ul acridinium ester working solution were drawn into the reaction cup, and the reaction was performed for 15min for detection. 5ug / ml of the above anti-hIgM series antibodies were added to the acridinium ester working solution of the experimental group, and the control group contained an equal volume of anti-hIgM series antibody diluent. The sample is an interference sample containing heterophilic antibodies or RF. The experimental results show that the experimental group has a significant elimination effect on false positive specimens, indicating that the above anti-hIgM series antibodies have a significant blocking effect, and are also better than the mainstream similar raw material A on the market.
[0109] Table 4 Chemiluminescence platform IgG1 (HIV P24) blocking data
[0110]
[0111]
[0112] 2.2 Verify the blocking effect of the above anti-hIgM series antibodies (IgG1 subclass) on the chemiluminescence platform cTnI antibody pairing
[0113] The cTnI antibody (IgG1 subclass) was paired, coupled with magnetic beads and acridinium ester, respectively, and the following reaction procedure was used on the chemiluminescence instrument ishine2910: 50ul sample, 50ul magnetic bead working solution, 50ul acridinium ester working solution were drawn into the reaction cup, and the reaction was performed for 15min for detection. 5ug / ml of the above anti-hIgM series antibodies were added to the acridinium ester working solution of the experimental group, and the control group contained an equal volume of anti-hIgM antibody diluent. The sample is an interference sample containing heterophilic antibodies or RF. The experimental results showed that the experimental group had a significant elimination effect on false positive specimens, indicating that the above anti-hIgM series antibodies had a significant blocking effect, and were also superior to the mainstream raw material A on the market.
[0114] Note: The smaller the value, the weaker the reaction and the better the blocking effect.
[0115] Table 5 Chemiluminescence platform IgG1 (cTnI) blocking data
[0116]
[0117] 2.3 The blocking effect of the above anti-hIgM series antibodies (IgG2a subclass) was verified on the IgG2a subtype pairing model of the chemiluminescence platform
[0118] The selected IgG2a antibodies (purchased from Feipeng Bio) were paired, coupled with magnetic beads and acridinium esters, respectively, and the following reaction procedure was used on the chemiluminescence instrument ishine2910: 50ul sample, 50ul magnetic bead working solution, 50ul acridinium ester working solution were drawn into the reaction cup, and the reaction was performed for 15min for detection. 5ug / ml of the above anti-hIgM series antibodies (IgG2a subclass) were added to the acridinium ester working solution in the experimental group, and the control group contained an equal volume of anti-hIgM antibody diluent. The sample is an interference sample containing heterophilic antibodies or RF. The experimental results show that the experimental group has a significant elimination effect on false positive specimens, indicating that the above anti-hIgM series antibodies have a significant blocking effect, and are also slightly better than the mainstream raw material A in the market.
[0119] Note: The smaller the value, the weaker the reaction and the better the blocking effect.
[0120] Table 6 Chemiluminescent platform IgG2a blocking data
[0121] Sample No. HAMA Sample 4 HAMA Sample 5 HAMA Sample 6 HAMA Sample 7 Control 1: Anti-hIgM antibody diluent blank control 135329 282462 350184 7692 Comparison 2: Mainstream raw material A in the market 9806 35522 72515 1844 Anti-IgMRmb10 3123 7826 2685 1439 Anti-IgMRmb19 2010 7211 2540 1555 Anti-IgMRmb20 1970 7627 2678 1377
[0122] 2.4 Verification of the blocking effect of the above anti-hIgM series antibodies (IgG2b subclass) on the IgG2b subtype pairing model of the chemiluminescence platform
[0123] The selected IgG2b antibody (purchased from Feipeng Bio) was paired, coupled with magnetic beads and acridinium ester respectively, and the following reaction procedure was used on the chemiluminescence instrument ishine2910: 50ul sample, 50ul magnetic bead working solution, 50ul acridinium ester working solution were drawn into the reaction cup, and the reaction was performed for 15min for detection. 5ug / ml of the above anti-hIgM series antibodies were added to the acridinium ester working solution of the experimental group, and the control group contained an equal volume of anti-hIgM antibody diluent. The sample is an interference sample containing heterophilic antibodies or RF. The experimental results show that the experimental group has a significant elimination effect on false positive specimens, indicating that the above anti-hIgM has a significant blocking effect, and is also slightly better than the mainstream raw material A on the market.
[0124] Note: The smaller the value, the weaker the reaction and the better the blocking effect.
[0125] Table 7 Chemiluminescent platform IgG2b blocking data
[0126]
[0127] 2.5 Verification of blocking effect on cTnI pairing on fluorescent immunochromatography platform
[0128] The CTNI antibodies (IgG1 subclass antibodies, purchased from Feipeng Bio) were paired, smeared and marked separately. The experimental group used mouse IgG1 series, and the sample pads were treated with the above-mentioned anti-hIgM antibody and the mainstream raw material B on the market, respectively, while the sample pads of the control group were not treated. False positive specimens were tested separately, and the experimental results showed that the experimental group had a significant elimination effect on false positive specimens, indicating that the above-mentioned anti-hIgM had a significant blocking effect, and was also slightly better than the mainstream raw material B on the market.
[0129] Note: The smaller the value, the weaker the reaction and the better the blocking effect.
[0130] Table 8 IgG1 blocking data of fluorescent immunochromatography platform
[0131]
[0132] 2.6 Verification of blocking effect on HIV p24 antigen detection pairing on immunocolloidal gold platform
[0133] HIV p24 antibodies (purchased from Feipeng Bio, IgG1 subclass) were paired, smeared and marked separately, and the experimental group used mouse IgG1 series. The sample pads were treated with anti-hIgM series antibodies and the mainstream raw material B on the market, respectively, and the sample pads of the control group were not treated; false positive specimens were tested separately, and the experimental results showed that the experimental group had a significant elimination effect on false positive specimens, indicating that the above anti-hIgM series antibodies played a significant blocking effect, and were also slightly better than the mainstream raw material B on the market.
[0134] Note: Color intensity is expressed in numbers. The smaller the number, the stronger the color. B means no color. "+" means the color intensity is 0.5 color cards.
[0135] Table 9 Colloidal gold platform IgG1 blocking data
[0136]
[0137] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
[0138] The partial amino acid sequences involved in this application are as follows:
[0139] Table 10 Amino Acid Sequence
[0140]
[0141]
[0142]
[0143]
[0144]
[0145]
[0146]
[0147]
[0148]
[0149]
[0150]
[0151]
Claims
1. An antibody or a functional fragment thereof, comprising three complementary determining regions of a heavy chain variable region having an amino acid sequence of any one of SEQ ID NO: 17, 18, 38, 56, 74, 92, 93, 94, 95, 120, 138, 177, 195, 214, 232, 250, 268, 286, 304, 322 or 340 and three complementary determining regions of a light chain variable region having an amino acid sequence of any one of SEQ ID NO: 19, 39, 57, 75, 96, 121, 139, 140, 141, 142, 143, 144, 145, 146, 178, 196, 215, 233, 251, 269, 287, 305, 323 or 341.
2. The antibody or functional fragment thereof according to claim 1, characterized in that: The HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 or LCDR3 of the variable region is defined by any one system or a combination of multiple systems of Kabat, Chothia, IMGT, AbM or Contact.
3. An antibody or a functional fragment thereof, characterized in that: The antibody or its functional fragment comprises a CDR sequence of any of the following number combinations: 。 4. An antibody or a functional fragment thereof, comprising a heavy chain variable region and / or a light chain variable region, characterized in that: The amino acid sequence of the heavy chain variable region is as shown in any one of SEQ ID NO:17, 18, 38, 56, 74, 92, 93, 94, 95, 120, 138, 177, 195, 214, 232, 250, 268, 286, 304, 322 or 340; the amino acid sequence of the light chain variable region is as shown in any one of SEQ ID NO:19, 39, 57, 75, 96, 121, 139, 140, 141, 142, 143, 144, 145, 146, 178, 196, 215, 233, 251, 269, 287, 305, 323 or 341.
5. The antibody or functional fragment thereof according to any one of claims 1 to 4, wherein the heavy chain variable region and the light chain variable region are selected from any combination of: Optionally, the antibody or its functional fragment further comprises a constant region; Optionally, the constant region includes a heavy chain constant region and / or a light chain constant region; Optionally, the heavy chain constant region is selected from the heavy chain constant region of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD; the light chain constant region is selected from the κ type or λ type light chain constant region; Optionally, the species of the constant region is cattle, horse, pig, sheep, goat, rat, mouse, dog, cat, rabbit, donkey, deer, mink, chicken, duck, goose or human; Optionally, the species origin of the constant region is mouse; Optionally, the heavy chain constant region sequence is as shown in any one of SEQ ID NO: 15, 119 or 213 or has at least 80% identity thereto; Optionally, the light chain constant region sequence is as shown in SEQ ID NO: 16 or has at least 80% identity thereto; Optionally, the functional fragment is selected from any one of F(ab')2, Fab', Fab, Fv and scFv of the antibody; Optionally, the antibody or functional fragment binds to human IgM.
6. An antibody or a functional fragment thereof, comprising a heavy chain and / or a light chain, characterized in that: The amino acid sequence of the heavy chain is shown in any one of SEQ ID NO: 20, 21, 40, 58, 76, 97, 98, 99, 100, 122, 147, 179, 197, 216, 234, 252, 270, 288, 306, 324, 342; the amino acid sequence of the light chain is shown in any one of SEQ ID NO: 22, 41, 59, 77, 101, 123, 148, 149, 150, 151, 152, 153, 154, 155, 180, 198, 217, 235, 253, 271, 289, 307, 325, 343; Optionally, the antibody or its functional fragment comprises a heavy chain and a light chain of any combination of the following numbers: 。 7. A nucleic acid, characterized in that The nucleic acid encodes the antibody or a functional fragment thereof according to any one of claims 1 to 6.
8. A cell, characterized in that The cell comprises the nucleic acid of claim 7.
9. A method for preparing the antibody or functional fragment thereof according to any one of claims 1 to 6, characterized in that: The method comprises culturing the cell of claim 8.
10. Use of the antibody or functional fragment thereof according to any one of claims 1 to 6 in immunoassay or in the preparation of immunoblocking agents.
11. A blocking agent, characterized in that The blocking agent comprises the antibody or a functional fragment thereof according to any one of claims 1 to 6.
12. A detection reagent or kit, characterized in that: The reagent or kit comprises the antibody or functional fragment thereof according to any one of claims 1 to 6, or the blocking agent according to claim 11.
13. A method for reducing / eliminating endogenous interference, characterized in that: The antibody or functional fragment thereof according to any one of claims 1 to 6 or the blocking agent according to claim 11 is added to the immunoassay system.
14. A method of immunoassay, characterized in that: The method comprises: adding the antibody or functional fragment thereof according to any one of claims 1 to 6, or the blocker according to claim 11, to an immunoassay system.
15. A method for detecting human IgM, characterized in that: The method comprises: contacting the antibody or functional fragment thereof according to any one of claims 1 to 6 with a sample from the subject under conditions sufficient for a binding reaction to occur; and detecting immune complexes generated by the binding reaction.
Citation Information
Patent Citations
Anti-IgM monoclonal antibody
CN112094352A
Anti-human IgM antibody and application thereof
CN115677856A
Anti-human IgM antibody as well as preparation method and application thereof
CN116143931A
Cited By
Monoclonal antibody for identifying avian infectious bronchitis virus H120 strain and application thereof
CN122562941A
